In a deal described by the two companies as a “strategic alliance,” AbbVie has paid iStar Medical SA $60m to continue the development and commercialization of iSTAR’s MINIject glaucoma device.
The upfront payment will “go straight to supporting us advance the further clinical and commercial development of MINIject,” iSTAR Medical...